Susan E Krown

Prof. Susan E Krown

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2020 in The Lancet
Verified
Journal Article
Closed access
SKSusan E Krown
Susan E Krown
CMCarlee B Moser
Carlee B Moser
PMPatrick MacPhail
Patrick MacPhail
RMRoy M Matining
Roy M Matining
CGCatherine Godfrey
Catherine Godfrey
BGBrian Gottshall
Brian Gottshall

1 March 2002 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
SKSusan E Krown
Susan E Krown
PLPing Li
Ping Li
JRJamie H. Von Roenn
Jamie H. Von Roenn
JPJosephine Paredes
Josephine Paredes
JHJie Huang
Jie Huang
MTMarcia A. Testa
Marcia A. Testa
We wished to evaluate the efficacy and safety of a low and an intermediate daily dose of interferon-α2b (IFN-α2b) with didanosine in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi's sarcoma (KS). HIV-seropositive subjects with biopsy-confirmed cutaneous KS were randomized to receive either a low (1 million IU) or an intermediate (10 million IU) dose of IFN-α2b once daily with twice daily doses of didanosine. Treatment assignment was stratified by CD4 count. Response, toxicity, changes in CD4 counts, and survival were evaluated. Sixty-eight eligible subjects were accrued, 35 to low-dose and 33 to intermediate-dose IFN-α2b. The response rate was 40% in the low-dose group (95% CI, 24-58) and 55% in the intermediate-dose group (95% CI, 36-72) (p = 0.338). The median response duration was approximately 110 weeks in both groups. Intermediate-dose IFN induced grade 3/4 neutropenia more often (21% vs. 3%, p = 0.048) and grade 3/4 toxicity faster (p = 0.0231) and necessitated treatment discontinuation earlier for drug-related toxicities (p = 0.0416) than low-dose IFN. There were no significant differences in survival between the treatment groups. Baseline CD4 count was the only significant factor predicting response. Once-daily low-dose and intermediate-dose IFN-α2b induced similar response rates, which were achieved without optimal antiretroviral therapy. The slightly higher response rate in the intermediate-dose group was offset by its significantly poorer tolerance. These findings justify the use of lower, well-tolerated IFN doses for treatment of KS with currently used antiretroviral regimens.

15 April 2012 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
SKSusan E Krown
Susan E Krown
DRDebasmita Roy
Debasmita Roy
JLJeannette Y. Lee
Jeannette Y. Lee
BDBruce J. Dezube
Bruce J. Dezube
ERErin G. Reid
Erin G. Reid
DDDirk P. Dittmer
Dirk P. Dittmer
Purpose: The mammalian target of rapamycin is activated in Kaposi sarcoma (KS) and its inhibitor, rapamycin, has induced KS regression in transplant-associated KS. This study aimed to evaluate rapamycin's safety and toxicity in HIV-infected individuals with KS receiving antiretroviral therapy (ART), investigate rapamycin interactions with both protease inhibitor (PI)–containing and nonnucleoside reverse transcriptase inhibitor (NNRTI)–containing ART regimens, and assess clinical and biological endpoints including KS response and mammalian target of rapamycin-dependent signaling. Methods: Seven participants, 4 on PI-based and 3 on NNRTI-based ART, had rapamycin titrated to achieve trough concentrations of 5–10 ng/mL. Patients were monitored for safety and KS response. KS biopsies were evaluated for changes in phosphoribosomal S6 protein, and phospho-Akt expression. Interleukin 6 and vascular endothelial growth factor levels, HIV and KS-associated herpesvirus viral loads, and CD4 counts were monitored. Results: Despite pharmacokinetic interactions resulting in >200-fold differences in cumulative weekly rapamycin doses between participants on PI-containing and NNRTI-containing regimens, treatment was well tolerated. There were no significant changes in viral loads or cytokine levels; modest initial decreases in CD4 counts occurred in some patients. Three participants, all on PI-containing regimens and with higher rapamycin exposure, showed partial KS responses. Three of 4 subjects whose biopsies were studied at ≥day 50 showed decreased phosphoribosomal S6 protein staining. Conclusions: Rapamycin seems safe in HIV-infected individuals with KS and can, in some cases, induce tumor regression and affect its molecular targets. Significant pharmacokinetic interactions require careful titration to achieve target drug trough concentrations but may be exploited to achieve therapeutic benefit.

1 January 2011 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
HKHenry B Koon
Henry B Koon
BFBarbara Fingleton
Barbara Fingleton
JLJeannette Y Lee
Jeannette Y Lee
JGJulia T Geyer
Julia T Geyer
ECEthel Cesarman
Ethel Cesarman
SKSusan E Krown
Susan E Krown
Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. Serial Kaposi sarcoma biopsies assessed treatment effects on angiogenic factors and Kaposi sarcoma herpesvirus-latency associated nuclear antigen-1 (KSHV-LANA). We observed marked heterogeneity of KSHV-LANA expression. Although the small number of subjects whose response could be evaluated precluded definitive assessment of halofuginone's efficacy, we observed a significant decrease in type-I collagen only in halofuginone-treated lesions, but no effect on MMP-2. The trial design is applicable to future studies of topical agents.

3 October 2006 in Cancer
Verified
Journal Article
Closed access
PDF file
SKSusan E Krown
Susan E Krown
DNDonna Niedzwiecki
Donna Niedzwiecki
WHWen‐Jen Hwu
Wen‐Jen Hwu
LHLydia Hodgson
Lydia Hodgson
AHAlan N. Houghton
Alan N. Houghton
FBfor the Cancer and Leukemia Group B
for the Cancer and Leukemia Group B

1 September 2007 in Current Opinion in Oncology
Verified
Journal Article
Closed access
DDDirk P Dittmer
Dirk P Dittmer
SKSusan E Krown
Susan E Krown
Purpose of review To summarize major recent findings on the biology of human herpesvirus-8, i.e. Kaposi's sarcoma-associated herpesvirus, and the implications of these findings for Kaposi's sarcoma treatment. Recent findings Although reduced in incidence in developed countries since the introduction of highly active antiretroviral therapy, Kaposi's sarcoma incidence is still markedly increased in HIV-infected patients in resource-rich areas of the world and is a major complication among HIV-infected individuals in sub-Saharan Africa. The Akt/mammalian target of rapamycin pathway has emerged as a major driving force in Kaposi's sarcoma. In addition, the roles of p53, the Kaposi's sarcoma-associated herpesvirus viral cyclin and nuclear factor-κB in the development and progression of Kaposi's sarcoma are being further clarified, and therapeutic agents are being developed that may target these pathogenetic mechanisms. New Kaposi's sarcoma treatments should be considered that target the molecular interface between virus and host. Summary The growing knowledge of Kaposi's sarcoma biology provides multiple opportunities for rational targeted therapies. Further research is needed to better understand the mechanisms by which Kaposi's sarcoma develops and to develop therapeutic strategies that prevent resistance to treatment.